Table II.

Laboratory patient data before treatment with grazoprevir/elbasvir.

Variables	Value	Units	Reference range
Total protein	8.3	g/dl	6.5–8.2
Albumin	4	g/dl	3.5–5.5
Albumin/globulin ratio	0.93		1–1.8
Blood urea nitrogen	19.8	mg/dl	8.2–4.3
Creatinine	0.97	mg/dl	0.5–1
Total bilirubin	1.2	mg/dl	0.1–1.2
Direct bilirubin	0.5	mg/dl	0.1–0.6
Aspartate transaminase	32	U/l	10–35
Alanine transaminase	29	U/l	5–40
Alkaline phosphatase;	509	U/l	100–340
Lactate dehydrogenase	113	U/l	110–220
γ-glutamyl transpeptidase	18	U/l	0–30
Total cholesterol	99	mg/dl	130–219
Triglyceride	47	mg/dl	30–149
Na	138	mmol/l	135–146
K	4.2	mmol/l	3.5–4.6
Cl	104	mmol/l	96–110
White blood cells	1,410	/µl	4,700–8,700
Red blood cells	375×104	/µl	370–490
Hemoglobin	10	g/dl	13–17
Hematocrit	31.3	%	35–45
Platelets	2.9×104	/µl	15–35
Neutrophils	78.5	%	38–71.9
Eosinophils	1	%	0.2–6.8
Basophils	0	%	0–1
Lymphocytes	11.5	%	26–46.6
Monocytes	9.5	%	2.3–7.7
Prothrombin time	49	%	80–100

Laboratory data revealed severe pancytopenia due to increased splenic function. The patient's FIB4 index was 11.27.